Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_assertion type Assertion NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_head.
- NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_assertion description "[Poly(ADP-ribose) polymerase inhibitors (PARPi) are currently evaluated in clinical trials in combination with topoisomerase I (Top1) inhibitors against a variety of cancers, including colon carcinoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.
- NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_assertion evidence source_evidence_literature NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.
- NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_assertion SIO_000772 23653048 NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.
- NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_assertion wasDerivedFrom befree-20140225 NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.
- NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_assertion wasGeneratedBy ECO_0000203 NP404850.RAmaHUTSBrKQxVpDCiMehxUlu0bUk_k0ob9qzRVk3mPdQ130_provenance.